Theralase Technologies Stock Price, News & Analysis (CVE:TLT)

C$0.23 0.01 (2.27 %)
(As of 01/16/2018 04:43 AM ET)
Previous CloseC$0.22
Today's RangeC$0.22 - C$0.23
52-Week RangeC$0.19 - C$0.55
Volume189,260 shs
Average Volume334,157 shs
Market CapitalizationC$27.83 million
P/E Ratio-4.50
Dividend YieldN/A
Beta-0.1

About Theralase Technologies (CVE:TLT)

Theralase Technologies Inc. designs, develops, manufactures, and markets super-pulsed cold laser technology for a range of human, companion animal, and equine applications. The company operates in two divisions, Therapeutic Laser Technology and Photo Dynamic Therapy. It engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of nerve, muscle, tendon, ligament, joint, and wound conditions through the elimination of pain, reduction of inflammation, and acceleration of tissue healing. The company is also involved in the research, development, and commercialization of the patented and patent pending TLC-3000 medical laser and photo dynamic compound anti-cancer technology through preclinical research, clinical trials, and technology development to destroy cancers for oncological applications, as well as to destroy bacteria for human, animal, and sterilization applications. In addition, it operates a full service medical rehabilitation clinic in Toronto, Ontario for training and education of health-care practitioners. The company sells its products to licensed healthcare practitioners in Canada, the United States, and internationally. Theralase Technologies Inc. has strategic partnerships with University Health Network, Ontario Centers of Excellence for Photonics, National Research Council of Canada, Virginia Tech, The Scripps Research Institute, Mayo Clinic, University of Buffalo, and JSS Medical Research, as well as clinical research agreements with Princess Margaret Cancer Centre and University Health Network. The company was founded in 1995 and is based in Toronto, Canada.

Receive TLT News and Ratings via Email

Sign-up to receive the latest news and ratings for TLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorHealthcare
SymbolCVE:TLT
CUSIPN/A
Phone+1-416-6995273

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-4.5
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.05)
Net IncomeN/A
Net Margins-346.71%
Return on Equity-175.04%
Return on Assets-153.91%

Miscellaneous

EmployeesN/A
Outstanding Shares126,482,000

Theralase Technologies (CVE:TLT) Frequently Asked Questions

What is Theralase Technologies' stock symbol?

Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."

How were Theralase Technologies' earnings last quarter?

Theralase Technologies Inc. (CVE:TLT) released its earnings results on Wednesday, November, 29th. The company reported ($0.01) EPS for the quarter. Theralase Technologies had a negative net margin of 346.71% and a negative return on equity of 175.04%. View Theralase Technologies' Earnings History.

When will Theralase Technologies make its next earnings announcement?

Theralase Technologies is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Theralase Technologies.

Who are some of Theralase Technologies' key competitors?

Who are Theralase Technologies' key executives?

Theralase Technologies' management team includes the folowing people:

  • Roger Dumoulin-White, President, Chief Executive Officer, Director
  • Kristina Hachey, Chief Financial Officer
  • Michael Borovec, Director of Investor Relations
  • Matthew Perraton, Director
  • Guy John Anderson, Independent Director (Age 1)
  • Randall Bruder, Independent Director

How do I buy Theralase Technologies stock?

Shares of Theralase Technologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Theralase Technologies' stock price today?

One share of Theralase Technologies stock can currently be purchased for approximately C$0.23.

How big of a company is Theralase Technologies?

Theralase Technologies has a market capitalization of C$27.83 million.

How can I contact Theralase Technologies?

Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273.


MarketBeat Community Rating for Theralase Technologies (TLT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  25
MarketBeat's community ratings are surveys of what our community members think about Theralase Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Theralase Technologies (CVE:TLT) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Theralase Technologies (CVE:TLT) Earnings History and Estimates Chart

Earnings by Quarter for Theralase Technologies (CVE:TLT)

Theralase Technologies (CVE TLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018        
11/29/2017Q3 2017C($0.01)ViewN/AView Earnings Details
8/29/2017Q2 2017C($0.02)ViewN/AView Earnings Details
5/30/2017Q1 2017C($0.01)ViewN/AView Earnings Details
5/1/2017Q4 2016C($0.01)ViewN/AView Earnings Details
11/29/2016Q3 2016C($0.02)C($0.01)ViewN/AView Earnings Details
8/29/2016Q2 2016C($0.01)ViewN/AView Earnings Details
5/27/2016Q1 2016C($0.01)ViewN/AView Earnings Details
4/29/2016Q4 2015C($0.01)ViewN/AView Earnings Details
11/27/2015Q3 2015C($0.01)C($0.02)ViewN/AView Earnings Details
8/28/2015Q2 2015C($0.01)C($0.01)ViewN/AView Earnings Details
5/29/2015Q1 2015C($0.01)C($0.01)ViewN/AView Earnings Details
4/30/2015Q4 2014C($0.01)ViewN/AView Earnings Details
11/28/2014Q3 2014C($0.02)ViewN/AView Earnings Details
8/29/2014Q2 2014C($0.01)C($0.01)ViewN/AView Earnings Details
5/30/2014Q1 2014C($0.01)ViewN/AView Earnings Details
4/30/2014Q4 2013C($0.01)ViewN/AView Earnings Details
5/30/2013Q1 2013C($0.01)ViewN/AView Earnings Details
11/29/2012Q3 2012C($0.01)ViewN/AView Earnings Details
5/31/2012Q1 2012C($0.01)ViewN/AView Earnings Details
4/30/2012Q4 2011C($0.04)ViewN/AView Earnings Details
11/28/2011Q3 2011C($0.01)ViewN/AView Earnings Details
8/30/2011Q2 2011C($0.01)ViewN/AView Earnings Details
6/29/2011Q1 2011C($0.01)ViewN/AView Earnings Details
11/30/2010Q3 2010C($0.01)ViewN/AView Earnings Details
8/31/2010Q2 2010C($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Theralase Technologies (CVE:TLT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Theralase Technologies (CVE:TLT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Theralase Technologies (CVE TLT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Theralase Technologies (CVE TLT) News Headlines

Source:
DateHeadline
IIROC Trading Resumption - TLTIIROC Trading Resumption - TLT
www.bizjournals.com - November 14 at 10:26 AM

SEC Filings

Theralase Technologies (CVE:TLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Theralase Technologies (CVE TLT) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.